Updates
Accelerate Diagnostics Expands Antimicrobials in New CE-Marked Accelerate PhenoTest™ BC kit

Aug 02, 2019 — Today we announced the release and CE marking of our latest Accelerate PhenoTest™ BC kit, declaring conformity to the European Directive 98/79/EC on in vitro diagnostic medical devices. The new CE-IVD Accelerate PhenoTest™ BC kit now includes phenotypic antimicrobial susceptibility test (AST) results for ceftazidime-avibactam and ceftolozane-tazobactam for Enterobacteriaceae and P. aeruginosa bacteria, and trimethoprim-sulfamethoxazole […]

Continue reading


University of Iowa Hospitals & Clinics announces adoption of Accelerate Pheno

Jan 16, 2019 — University of Iowa Hospitals & Clinics recently shared their adoption of the Accelerate Pheno™ system as a “new technology that helps diagnose and treat sepsis—a potentially life-threatening infection in the blood—faster than ever before.” Get the full story from UI Health Care Quick story excerpt: “Every hour counts,” explains Bradley Ford, MD, PhD, medical director […]

Continue reading


Accelerate Diagnostics announces preliminary 2018 fourth quarter and full-year financial results

Jan 06, 2019 — Added 117 commercially contracted U.S. instruments in Q4, doubling the regional installed base TUCSON, Ariz., Jan. 6, 2019 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter ending December 31, 2018. The company reported a 127.2% increase in U.S. instruments placed under commercial contract during the fourth quarter, and […]

Continue reading


Accelerate Diagnostics reports Q3 2018 financial results

Nov 06, 2018 — Revenue Placements up 40 Percent in U.S., Total Revenue up 64 Percent TUCSON, Ariz., Nov. 6, 2018 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced financial results for the quarter ending September 30, 2018. The company reported a 40% increase in U.S. instruments placed under commercial contract, and revenue for the quarter of $1.3 million, an […]

Continue reading


See all news

See the Latest data from IDWeek™

See the Latest data from ASM


Media kit

Media contact

Andy Chasteen
520.365.3100
achasteen@axdx.com


Company information

About the company
Bios
Our products


Digital assets

Enter your email address below for access to photos, logos and videos.

See Terms and Use Policy


Connect with us

  Like us on Facebook
  Follow us on Twitter
  See us on Linkedin
  Visit us on Google+

Upcoming Events
ASM Microbe 2019

June 20–24, 2019
San Francisco

Learn more

Want to hear when we announce our next event?

Stay up to date with Accelerate by joining our mailing list.

Sign up today
Past Events
ECCMID 2019

April 13-16, 2019
Amsterdam, Netherlands

Learn more

SCCM 2019

February 17-20, 2019
San Diego, California

Learn more

MEDLAB 2019

February 4 - 7, 2019
Dubai World Trade Centre, UAE

Learn more

RICAI 2018

December 17 - 18, 2018
Palais des Congrès de Paris

Learn more

AMCLI 2018

November 10 - 13, 2018
Palacongressi Di Rimini, IT

Learn more

IDWeek 2018

October 3-7, 2018
San Francisco, CA

Learn more

Over the past several years, Accelerate Diagnostics, together with our scientific collaborators, conducted numerous scientific studies supporting the exciting capabilities of our ID/AST System. Many of these studies resulted in posters presented at international conferences and peer-reviewed publications. We have conducted over 87,000 internal identification and susceptibility experiments across a panel of more than 20 of the most clinically prevalent species in sample types such as positive blood cultures and BALs. These studies demonstrated compelling performance versus reference and comparator methods, the results of which have been consistently duplicated by our clinical research partners. Below you will find links to some of these posters and publications.


These publications may include information from one or more organism/antimicrobial combinations that are research use only and not for use in diagnostic procedures.

Certain uses of devices included in these publications may not have been approved or cleared by the U.S. Food and Drug Administration or other regulatory bodies.

See product labeling for instructions for use, warnings, and limitations specific to each product and region.

Okay, I understand. Show me the publications.